Alosetron

Alosetron
Clinical data
Trade names	Lotronex
AHFS/Drugs.com	Monograph
MedlinePlus	a601230
Routes of; administration	Oral (tablets)
ATC code	A03AE01 (WHO) ;
Legal status
Legal status	US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	50–60%
Protein binding	82%
Metabolism	Hepatic (including CYP2C9, CYP3A4 and CYP1A2)
Elimination half-life	1.5–1.7 hours
Excretion	Renal 73%, faecal 24%
Identifiers
	IUPAC name 5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one;
CAS Number	122852-42-0 ;
PubChem CID	2099;
IUPHAR/BPS	2296;
DrugBank	DB00969 ;
ChemSpider	2015 ;
UNII	13Z9HTH115;
KEGG	D07129 ;
ChEBI	CHEBI:253342 ;
ChEMBL	ChEMBL1110 ;
CompTox Dashboard (EPA)	DTXSID6044278 ;
Chemical and physical data
Formula	C17H18N4O
Molar mass	294.358 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1nc[nH]c1CN2CCc4c(C2=O)c3ccccc3n4C;
	InChI InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19) ; Key:JSWZEAMFRNKZNL-UHFFFAOYSA-N ;
	(verify)

Alosetron, sold under the brand name Lotronex among others, is a 5-HT₃ antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

It was patented in 1987 and approved for medical use in 2002. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.